Proposed mechanisms of action for prostate cancer vaccines. - Wikidata - awgldk - TriplyDB

Proposed mechanisms of action for prostate cancer vaccines.

Proposed mechanisms of action for prostate cancer vaccines.

http://www.wikidata.org/entity/Q35174754

about

Application of radiation technology in vaccines development Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy The value of EGFRvIII as the target for glioma vaccines.Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis.Applying biodegradable particles to enhance cancer vaccine efficacy.Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines.Prostate cancer vaccines: Update on clinical development.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

P2860

Q26798165-678BC41C-1F6C-49CB-9160-515523F948BA Q28066199-2F964388-6150-4524-988F-16772D5E6400 Q35627573-AE0BD5A8-67BA-4428-97D9-AE4B06590645 Q36396099-08989EDF-6E11-4263-83C9-F22E2B31AEE6 Q37531813-690B6BB2-D03A-4C4C-BBA4-1B76AE311B2C Q38212549-C6EE9CAF-011C-4960-B6E1-1DDEBDBE1756 Q39037485-F4BEA8E8-541D-4D2D-B8F0-947D99795283 Q41220895-D698B18E-77BC-4EE8-8A67-B3897A6C0713 Q47325431-9622FE6A-F3EA-4F9D-85B9-E069C31F64C3

P2860

Proposed mechanisms of action for prostate cancer vaccines.

http://www.wikidata.org/entity/Q35174754

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Proposed mechanisms of action for prostate cancer vaccines.

@ast

Proposed mechanisms of action for prostate cancer vaccines.

@en

type

label

Proposed mechanisms of action for prostate cancer vaccines.

@ast

Proposed mechanisms of action for prostate cancer vaccines.

@en

prefLabel

Proposed mechanisms of action for prostate cancer vaccines.

@ast

Proposed mechanisms of action for prostate cancer vaccines.

@en

P1433

Q35174754-AB625946-0E80-4118-B1F6-B6A5DE3274D9

P1476

Q35174754-0B6072F3-7538-43FB-82A1-97D2B8A1A67D

P2093

Q35174754-296B2839-FF9B-4FAD-BBF9-2BA75E22021A

Q35174754-340646D3-CBBF-47D7-8A22-38853DF06B3A

Q35174754-7DE5295B-7D02-4FCC-A133-7C4E4C0C01C5

P2860

Q35174754-0590FE2B-8833-451E-8B9D-BAA3137F1DCC

Q35174754-066A0119-2AA2-4B5F-B2E8-5E0F31A5552A

Q35174754-084FA5D8-D707-4355-88FC-D4F13B1E44CB

Q35174754-08500467-8A0A-4A7A-8FC5-BE9F8811E927

Q35174754-0876456B-58EE-4C25-AC7B-AD787400A20D

Q35174754-0887DFA8-4336-4342-8431-BCB8C9CC518E

Q35174754-09D96B77-F6B1-466C-8940-BA3D47E6B4F8

Q35174754-0AE97D7E-7EE2-4EE1-9876-E320FC6DF7E0

Q35174754-0B780221-E713-429C-8386-4EF919CB5D10

Q35174754-0C75BB5F-2C8A-4EE6-A095-5D1BA55ADDF6

P2888

Q35174754-C1012195-BA89-4C49-B17C-A235455BB717

P304

Q35174754-6A86A40A-360C-44E6-9872-28A4408B9B0C

P31

Q35174754-6F29FD1F-E7D0-44A7-86F5-CC6FA244BA00

P356

Q35174754-5E7C3725-CE98-404E-BF7D-F81E2BAEF3BD

P407

Q35174754-A2FAC4EB-968F-4AA6-BFA4-6D824E38585C

P433

Q35174754-63A3B296-8F63-4D2C-AB6E-DA4D19E36FF3

P478

Q35174754-1BF7FA76-36B8-4F8E-8064-0DB6F5DC0822

P50

Q35174754-D37F074E-5EB8-46EE-A1DB-362BDA74392A

P577

Q35174754-B78D9784-F09B-4045-864E-F27BE747DB88

P5875

Q35174754-44E955E1-BE67-4B91-A911-3EAD3ED530E4

P698

Q35174754-3E867FC6-0F5A-4E5C-B22A-59303594E43F

P932

Q35174754-2EED7667-303A-415E-87E3-D0778229C521

P356

P1433

Nature Reviews Urology

P1476

Proposed mechanisms of action for prostate cancer vaccines

@en

P2093

Caitlin D Lemke

http://www.w3.org/2001/XMLSchema#string

David M Lubaroff

http://www.w3.org/2001/XMLSchema#string

Sean M Geary

http://www.w3.org/2001/XMLSchema#string

P2860

The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro

Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Cancer statistics, 2012

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Toll-like receptors in the induction of the innate immune response

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Dendritic cells: specialized and regulated antigen processing machines

P2888

P304

149-160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRUROL.2013.8

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235521693

http://www.w3.org/2001/XMLSchema#string

P698

23399727

http://www.w3.org/2001/XMLSchema#string

P932

4358823

http://www.w3.org/2001/XMLSchema#string